Dependence on imported APIs risks supply chains and drives policy to boost domestic API manufacture and regulatory compliance.
Dependence on imported Active Pharmaceutical Ingredients (APIs) from China creates supply chain and quality vulnerabilities for India's pharmaceutical sector, while stringent international and domestic regulatory requirements, pricing pressures, competition, and patent disputes constrain export potential. Recommended responses include diversifying API sources, developing indigenous API manufacturing via incentives and public private partnerships, strengthening regulatory and quality standards to meet international norms, investing in R&D and biopharmaceutical innovation, and pursuing balanced IP policies alongside enhanced export market access and global public health collaboration. (AI Summary)
Dependence on imported Active Pharmaceutical Ingredients (APIs) from China creates supply chain and quality vulnerabilities for India's pharmaceutical sector, while stringent international and domestic regulatory requirements, pricing pressures, competition, and patent disputes constrain export potential. Recommended responses include diversifying API sources, developing indigenous API manufacturing via incentives and public private partnerships, strengthening regulatory and quality standards to meet international norms, investing in R&D and biopharmaceutical innovation, and pursuing balanced IP policies alongside enhanced export market access and global public health collaboration. (AI Summary)
TaxTMI